格卡瑞韦/哌仑他韦

格卡瑞韦/哌仑他韦
组成
[[格卡瑞韦（英语：Glecaprevir）]]	NS3/NS4A（英语：Hepatitis C virus nonstructural protein 4A）抑制剂
[[哌仑他韦（英语：pibrentasvir）]]	NS5A（英语：Hepatitis C virus nonstructural protein 5A）抑制剂
临床资料
商品名（英语：Drug nomenclature）	Mavyret, Maviret, others
AHFS/Drugs.com	Monograph
MedlinePlus	a617039
核准状况	美 DailyMed: and pibrentasvir Glecaprevir and pibrentasvir;
怀孕分级	澳: B1 ; ;
给药途径	口服给药
ATC码	J05AP57 (WHO) ;
法律规范状态
法律规范	澳：限医生处方（S4）; 加：处方药（℞-only）; 欧：Rx-only; 英：处方药（℞-only） (POM); 美：处方药（℞-only）; 处方药（℞-only）;
识别信息
KEGG	D11014;

格卡瑞韦/哌仑他韦（Glecaprevir/pibrentasvir， G/P）是一种用于治疗丙型肝炎的复方药^[4]。内含格卡瑞韦（英语：Glecaprevir）和哌仑他韦（英语：pibrentasvir）^[5]。对丙型肝炎的六型病毒皆有效^[4]。治疗十二周后，81% 至 100% 的患者体内未再检出丙型肝炎病毒^[6]。此药物需每日口服一次，随餐服用^[4]。

最常见的副作用包括头痛、腹泻和疲劳^[6] ^[7]。对于患有乙型肝炎的患者，可能会发生病毒再活化^[7]。中度至重度肝病患者不建议使用此药物^[6]。格卡瑞韦会阻断丙型肝炎病毒非结构蛋白3（NS3）/4A（英语：Hepatitis C virus nonstructural protein 4A）蛋白酶，而哌仑他韦则会阻断非结构蛋白5A（英语：Hepatitis C virus nonstructural protein 5A）^[4]。

格卡瑞韦/哌仑他韦于 2017 年在美国和欧洲取得医疗使用许可^[5] ^[4]。名列世界卫生组织基本药物标准清单^[8]。

参考文件

^ Glecaprevir / pibrentasvir (Mavyret) Use During Pregnancy. Drugs.com. 10 October 2019 [30 March 2020].
^ Liver disease. Health Canada. 9 May 2018 [13 April 2024].
^ Maviret 100 mg/40 mg Film-coated Tablets - Summary of Product Characteristics (SmPC). (emc). 11 March 2020 [30 March 2020].
^ ^4.0 ^4.1 ^4.2 ^4.3 ^4.4 Maviret EPAR. European Medicines Agency (EMA). 17 August 2017 [30 March 2020]. （原始内容存档于30 December 2019）.
^ ^5.0 ^5.1 FDA approves Mavyret for Hepatitis C (新闻稿). U.S. Food and Drug Administration (FDA). 3 August 2017 [30 March 2020]. （原始内容存档于30 March 2020）.
^ ^6.0 ^6.1 ^6.2 FDA approves treatment for adults and children with all genotypes of hepatitis C and compensated cirrhosis that shortens duration of treatment to eight weeks. U.S. Food and Drug Administration (FDA). 26 September 2019 [1 October 2019]. （原始内容存档于27 September 2019）.
^ ^7.0 ^7.1 British national formulary : BNF 76 76. Pharmaceutical Press. 2018: 620. ISBN 9780857113382.
^ World Health Organization. World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. 2019. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.

[Drugs.com_pregnancy-1] Glecaprevir / pibrentasvir (Mavyret) Use During Pregnancy. Drugs.com. 10 October 2019 [30 March 2020].

[2] Liver disease. Health Canada. 9 May 2018 [13 April 2024].

[3] Maviret 100 mg/40 mg Film-coated Tablets - Summary of Product Characteristics (SmPC). (emc). 11 March 2020 [30 March 2020].

[EMA2017-4] 4.0 ^4.1 ^4.2 ^4.3 ^4.4 Maviret EPAR. European Medicines Agency (EMA). 17 August 2017 [30 March 2020]. （原始内容存档于30 December 2019）.

[FDA2017-5] 5.0 ^5.1 FDA approves Mavyret for Hepatitis C (新闻稿). U.S. Food and Drug Administration (FDA). 3 August 2017 [30 March 2020]. （原始内容存档于30 March 2020）.

[FDA2019-6] 6.0 ^6.1 ^6.2 FDA approves treatment for adults and children with all genotypes of hepatitis C and compensated cirrhosis that shortens duration of treatment to eight weeks. U.S. Food and Drug Administration (FDA). 26 September 2019 [1 October 2019]. （原始内容存档于27 September 2019）.

[BNF76-7] 7.0 ^7.1 British national formulary : BNF 76 76. Pharmaceutical Press. 2018: 620. ISBN 9780857113382.

[WHO21st-8] World Health Organization. World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. 2019. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.

[4]

[5]

[6]

[1]

[2]

[3]

[7]

[8]